In this section
Assorted resources on conditions connected to Cardiology.
Latest information on diseases in Dermatology.
A detailed look at conditions connected to Endocrinology.
Gastroenterology and Hepatology
In-depth material on Gastroenterology and Hepatology.
Assorted resources on conditions connected to Haematology.
Immunology, the immune system and immune-mediated diseases.
A detailed look at conditions connected to Infectious Diseases.
Neurology (CNS) and Pain
Learning materials and guidelines on Neurology (CNS) and Pain.
A detailed look at conditions connected to Oncology.
Assorted resources on conditions connected to Ophthalmology.
In-depth material on Respiratory conditions.
Latest information on diseases in Rheumatology.
Learning materials and guidelines on Urology.
-Agios Pharmaceuticals, Inc.a leader in the field of cellular metabolism developing and delivering innovative treatments for genetically defined diseases, announced that it has submitted a New Drug Application (NDA) for mitapivat (AG 348) to the FDA for the treatment of adults with pyruvate kinase (PK) deficiency.
AstraZeneca and MSD's Koselugo (selumetinib) has been granted conditional approval in the European Union (EU) for the treatment of symptomatic, inoperable plexiform neurofibromas (PN) in paediatric patients with neurofibromatosis type 1 (NF1) aged three years and above.
GlaxoSmithKline plc and Vir Biotechnology, Inc.announced final, confirmatory results from the Phase III COMET-ICE (COVID-19 Monoclonal antibody Efficacy Trial – Intent to Care Early) trial demonstrating that sotrovimab, an investigational SARS-CoV-2 monoclonal antibody, significantly reduced the risk of hospitalisation or death among high-risk adult outpatients with mild-to-moderate COVID-19.
You may be interested in...
Open-Label, Single-Arm, Multicenter, Phase II Trial of Lenvatinib for the Treatment of Patients With Anaplastic Thyroid Cancer
Purpose: Anaplastic thyroid cancer (ATC), an aggressive malignancy, is associated with a poor prognosis and an unmet need for effective treatment, especially for patients without BRAF mutations or NTRK or RET fusions.
Associations between artificial light at night and risk for thyroid cancer: A large US cohort study
Light at night (LAN) inhibits nighttime secretion of melatonin and may cause circadian disruption, which may be a risk factor for cancer. Recent studies have linked high LAN exposure with elevated breast cancer risk.